The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.
about
Acetaminophen for osteoarthritisVariability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectivesGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesUpper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now?Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control studySafety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use.Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicityFactors associated with the initiation of proton pump inhibitors in corticosteroid users.The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effectsEpidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells.Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical recordsPrevalence and risk factors of gastrointestinal disorders in patients with rheumatoid arthritis: results from a population-based survey in olmsted county, Minnesota.NSAIDs and gastrointestinal complications: new clinical challenges.Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.Drug use and upper gastrointestinal complications in children: a case-control studyComparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial.Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experimentsAnalyzing partially missing confounder information in comparative effectiveness and safety research of therapeuticsThermal rehabilitation and osteoarticular diseases of the elderly.Managing the adverse effects of nonsteroidal anti-inflammatory drugs.A benefit-risk assessment of the use of proton pump inhibitors in the elderly.A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States.Acetaminophen (paracetamol) oral absorption and clinical influences.Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend?Management of NSAID-associated peptic ulcer disease.Prevention and Treatment of NSAID Gastropathy.Trikatu, a herbal compound that suppresses monosodium urate crystal-induced inflammation in rats, an experimental model for acute gouty arthritis.The association between gastro-oesophageal reflux disease and subsequent rheumatoid arthritis occurrence: a nested case-control study from Taiwan.Management of osteoarthritis of the knee in younger patients.Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion.
P2860
Q24244676-90299D10-308C-4031-9B1F-10F62532DA14Q27012539-34E9A57F-004A-4426-B14F-561247EBAC62Q27026351-AA5A531E-2BF2-4480-BAE3-10772C1911B5Q28193564-DDF8EC58-6A2A-4BF3-B942-E2232E6FF559Q28211313-9AF61489-91A2-41E3-A4DD-2670F748BEB3Q31000488-B2672F11-8D4B-4D2B-AE3E-D33623566657Q33461805-5927F878-C351-4448-89FA-1573E45FC874Q33959603-4577C277-C0BA-43B1-9DE4-1C8B8520DA10Q34141425-859923AB-1A7A-4021-AE00-F300791A9B3AQ34597321-ADBBA288-499D-4281-9336-693FD3213FDDQ34986307-5A05A8B6-7E86-48AA-9457-E510F0562031Q35044973-AE8A09CD-8151-49F0-94B8-5EBC804EFA73Q35554369-E4C02F46-A371-459B-8CA2-EBCF2EEACDDAQ35569771-21B466D8-63A0-494B-92A8-6A0F9CD98DE2Q35579999-36CBFCAB-8C50-4E3A-89DE-EA41AE354349Q36326243-8333BCEE-4239-44A1-9D21-F98D7A5F32D7Q36331512-C337A4F8-A4D5-4D69-A5CE-DCF58E8135D4Q36388949-1EA5B011-4D2F-4B25-B062-24EFE437F02FQ36637992-E7A8B7C3-544D-4835-8FE8-6220D061D5DBQ36685004-B6D5C205-8AAA-47F4-A267-1D69B982A80BQ36861909-6B09CEC6-59FE-4B9D-9E9F-7E149AAA58D7Q37056117-50D47926-72E6-40DF-970A-84E63686AC69Q37204693-23A0E11E-740B-4607-9A95-7FC988FE46B2Q37960540-86A8890B-CC22-44EE-8270-C34E79EE7EA4Q38196383-B09E6779-B6AC-4CBD-94BE-527998AF3AC7Q38200112-05A5D61B-3CD9-4807-93D6-5479C72F4997Q38503401-D8E349A2-1155-4FC2-B87C-F8C4D8EBF061Q38541866-6F3864C9-2CFA-4B8D-A552-FE4B7D564C95Q38699305-B73177E0-2973-49B4-9433-6044EB2AD023Q41744470-9148E607-6B24-41F9-AEDE-C0EAF284FDF7Q43414960-2BABAD5F-6A85-444A-ACBD-769D14C2F8E1Q47119652-E24F8FE5-0C1B-418F-B284-23F43A1C2F8BQ49875684-66591824-5ECF-4F68-9D62-3671FC638116Q53602109-2C37E7CA-2F60-4FC6-AF02-F52852230A5B
P2860
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
The risk of upper gastrointest ...... d combinations of these agents
@nl
The risk of upper gastrointest ...... combinations of these agents.
@ast
The risk of upper gastrointest ...... combinations of these agents.
@en
The risk of upper gastrointest ...... combinations of these agents.
@en-gb
type
label
The risk of upper gastrointest ...... d combinations of these agents
@nl
The risk of upper gastrointest ...... combinations of these agents.
@ast
The risk of upper gastrointest ...... combinations of these agents.
@en
The risk of upper gastrointest ...... combinations of these agents.
@en-gb
prefLabel
The risk of upper gastrointest ...... d combinations of these agents
@nl
The risk of upper gastrointest ...... combinations of these agents.
@ast
The risk of upper gastrointest ...... combinations of these agents.
@en
The risk of upper gastrointest ...... combinations of these agents.
@en-gb
P2860
P921
P3181
P356
P1476
The risk of upper gastrointest ...... combinations of these agents.
@en
P2093
L A Garcia Rodríguez
S Hernández-Díaz
P2860
P2888
P304
P3181
P356
10.1186/AR146
P407
P577
2000-12-15T00:00:00Z